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Preface 
The present thesis is submitted to meet the requirements for attaining the Ph. D. degree at The 
Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark.  
 
The experimental work was performed at the Department of Pharmaceutics and Analytical 
Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen with Associate Professor, 
PhD Bente Gammelgaard, Primary ADME Scientist, PhD Lars Bendahl and Professor, PhD Bent 
Halling-Sørensen as supervisors.  
 
The main part of the experimental work of the PhD project has been published or submitted for 
publication in relevant scientific journals and copies of the papers are included in Appendices I-III. 
Furthermore, involvement in a manuscript on speciation of selenium compounds related to human 
selenium metabolism has led to co-author status on a review which is included in Appendix IV. This 
thesis gives an introduction, discussion and conclusion of the results obtained. Published results 
will be referred to as papers I-IV. Whenever relevant to the discussion, produced results that are 
not presented in the publications will be included. For details of the published studies the reader is 
referred to the appendices.  
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During my enrolment as a PhD student I spent three month in the laboratory of Assistant 
Professor, PhD Angeline S. Andrew at Dartmouth Medical School, Section of Biostatistics and 
Epidemiology, Hanover, New Hampshire, USA. Alteration of genetic pathways in a human bladder 
cancer cell line treated with methylseleninic acid was investigated by use of cDNA microarray and 
RT-PCR technologies. The work was outside the specific scope of this thesis and it is not further 
presented.  
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Summary 
Selenium is an essential trace element that exerts its effect via a number of selenoproteins. 
Selenoproteins are mainly involved in redox processes. Furthermore, several studies on cell lines, 
animal models and human intervention trials have shown cancer protective effects of selenium.  
 
Selenium metabolism in not fully elucidated and there is need for further research in this field as 
understanding of selenium metabolism may lead to better understanding of the cancer protective 
mechanism of selenium. So far, selenium excretion in human urine has been extensively 
investigated and the most important metabolites have been identified as selenosugars. Other end 
products of selenium metabolism are volatile species excreted via the breath. The aim of this PhD 
project was to investigate earlier stages in the metabolic pathways. In vitro experiments with an 
intestinal metabolism model were performed in order to investigate if selenium compounds are 
metabolized intestinally before being available to hepatic metabolism and here after to the whole 
organism.  
 
The metabolism of selenite and methylseleninic acid was studied in homogenized intestinal 
epithelial cell from pigs. The major selenium-containing metabolites in the supernatant of the 
incubated cells were detected by LC-ICP-MS and identified by LC-ESI-MS, either directly in the 
supernatant or after purification by preparative chromatography. Both species were reduced by 
glutathione and cysteine, the major thiol compounds present in gastric and intestinal lumen. The 
reduction of selenite and methylseleninic acid was spontaneous and did not require enzymatic 
activity. Neither of the reduction products identified have been identified in mammalian intestinal 
models before and the findings emphasize that selenite and methylseleninic acid are not 
bioavailable in their intact forms. 
 
Methylseleninic acid, which is often used as a model compound for methylated selenium amino 
acids, was also incubated in isolated rat hepatocytes to investigate hepatic metabolism of this 
species. Parallel to the intestinal model studies, metabolites excreted from the hepatocytes were 
detected by LC-ICP-MS and identified by LC-ESI-MS after purification by preparative 
chromatography and pre-concentration by lyophilisation. One major metabolite of methylseleninic 
acid was Se-methylselenocysteine, the same methylated selenium amino acid to which 
methylseleninic acid is considered a model compound. The metabolic findings in the intestinal and 
hepatic models combined indicate that methylseleninic acid may not be a relevant model 
compound for methylated selenium amino acid. Another metabolite was selenomethionine which is 
widely used in selenium intervention trials. 
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Dansk Resumé 
Selen er et essentielt grundstof, som udøver sin funktion via selenoproteiner, der hovedsageligt 
indgår i redoxprocesser. Endvidere har flere forsøg i cellelinier, dyremodeller og humane studier 
vist at selen har en beskyttende virkning mod kræft. 
 
Selens metabolisme er ikke fuldt verificeret. Opklaring af selens metabolisme er vigtig som led i 
forståelsen af den kræftbeskyttende virkning. Hidtil har meget forskning været fokuseret på 
identifikation af slutprodukter i urin, og de vigtigste metabolitter er nu fastslået at være 
selenosukkere. Andre slutprodukter i selenmetabolismen er små flygtige forbindelser, der udskilles 
via åndedrættet. Formålet med dette Ph.D. projekt var at undersøge tidligere trin i metabolismen. 
In vitro forsøg i en tarmmodel blev udført for at undersøge om relevante selenforbindelser 
metaboliseres før de optages og føres til leveren, for derefter at blive systemisk tilgængelige. 
 
Selenit og methylseleninsyre metabolisme blev undersøgt i homogeniserede epitelceller fra en 
svinetarm. Hovedmetabolitterne i supernatanten fra cellehomogenatet blev detekteret med LC-ICP-
MS og identificeret med LC-ESI-MS enten direkte i supernatanten eller efter oprensning med 
præparativ chromatografi. Både selenit og methylseleninsyre blev reduceret af glutathion og 
cystein som er thioler, der findes i relativ stor mængde i mave- og tarmvæske. Reaktionen forløber 
spontant og er ikke enzymatisk betinget. Reduktionsprodukterne, der kaldes selenotrisulfider og 
methylselenylsulfider, er ikke tidligere identificeret med LC-ESI-MS i tarmmodeller og resultatet 
tydeliggører, at selenit og methylseleninsyre ikke er biotilgængelige i deres native form. 
 
Methylseleninsyre, der ofte anvendes som modelstof for methylerede selenaminosyrer, blev 
yderligere inkuberet med isolerede leverceller fra en rotte. Leverceller anvendes som model for 
metabolisme i leveren. Ekstracellulære metabolitter blev detekteret med LC-ICP-MS og identificeret 
med LC-ESI-MS efter oprensning med præparativ chromatografi og opkoncentrering med 
frysetørring. Methylseleninsyre omdannedes til Se-methylselenocystein, den samme 
selenaminosyre, som det anvendes som modelstof for. Resultatet fra tarmmodellen og 
levermodellen tilsammen sætter spørgsmålstegn ved om methylseleninsyre er et relevant 
modelstof for methylerede selenaminosyrer. Selenomethionin, der er den forbindelse, der ofte 
anvendes i interventionsstudier, blev også identificeret som metabolit af methylseleninsyre. 
 - 10 - 
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1 Introduction 
1.1 Selenium Chemistry 
The common oxidation states of selenium are -2, 0, 4 and 6. In biological samples the most 
common oxidation state of selenium is -2 in forms of the protein-bound selenoamino acids 
selenocysteine (SeCys) and selenomethionine (SeMet). Biological samples contain other divalent 
selenium compounds such as methylated selenoamino acids and methylated forms of hydrogen 
selenide. Inorganic compounds with selenium in high oxidation states such as selenite (+4) and 
selenate (+6) are rarely found in biological samples. Selenium and sulfur compounds share some 
structural similarities but differ widely in chemical properties for example selenols are stronger 
acids than their related thiols and compounds with selenium in the -2 oxidation state are more 
reducing while compounds with selenium in the +4 and +6 oxidation state are more oxidizing than 
the related sulfur compound[4] 
1.2 Selenium and health 
Selenium is an essential trace element in humans and selenium deficiency can have adverse 
consequences for disease susceptibility and maintenance of optimal health[5]. Selenium functions 
through diverse physiological pathways via selenoproteins. A number of selenoproteins have been 
identified, however the function of all of them has not yet been determined[6,7]. The most 
abundant selenoproteins are involved in general defence against oxidative stress. Selenium has 
immunostimulant effect and selenium deficiency is linked to occurrence, virulence and disease 
progression of some viral infections. It is essential for male fertility and thyroid function[5].  
 
Since the publication of the first double-blind, placebo controlled intervention trial in which 
selenium supplementation caused reduction in overall cancer mortality and reduced the number of 
incidences of lung, prostate and colon cancer[8], selenium has gained much interest as a cancer 
preventive agent.  
 
Common sources of selenium are selenomethionine (SeMet) and selenocysteine (SeCys) from 
vegetable and animal food. Nutritional supplements represent another source of selenium that 
often contains selenite, selenate, SeMet and selenium enriched yeast. Recommended daily intake is 
50-70 µg/day which is considered adequate to prevent deficiency symptoms and keep the 
selenoproteins functioning[9].   
1.2.1 Selenium and cancer 
The cancer preventive mechanism of selenium is not understood; however the degree of protection 
is highly dependent on the chemical form of the ingested selenium, most likely because different 
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selenium compounds are metabolized in different pathways by the organism[10]. As DNA 
mutations caused by high cellular concentrations of reactive oxygen species (ROS) may lead to 
carcinogenesis[11] and antioxidants as general protectors against induced carcinogenesis is 
currently discussed[12], the antioxidant selenoproteins may play a role in the cancer preventive 
effect of selenium. However, in cancer intervention trials, doses are 3-4 times higher than the 
recommended daily intake; hence the cancer preventive effect might not be exerted entirely via 
the selenoproteins. A theory for the cancer preventive mechanism of selenium in which 
methylselenol (MeSeH) is a key metabolite has been suggested[13] and selenium compounds that 
are metabolized into MeSeH are considered to be efficient in cancer prevention. According to this 
theory Se-methylselenocysteine (Se-MeSeCys) which is believed to produce MeSeH when cleaved 
by the β-lyase enzymes and methylseleninic acid (MeSeA) which is believed to produce MeSeH by a 
series of reductions by thiols such as cysteine and glutathione[2] would be efficient cancer 
protective agents. Another theory of the cancer preventive mechanism of selenium is that selenium 
compounds in oxidation state +4 are most effective as they can inactivate critical cellular enzymes 
by oxidizing their sulfhydryl groups and thereby induce apoptosis[14]. According to this theory 
selenite and MeSeA would be efficient cancer protective agents. Interestingly, the most efficient 
cancer preventive species according to the proposed theories do not include selenomethionine, the 
principal species used in intervention trials.  
1.3 Selenium metabolism 
Selenium metabolism is most often described by different variations of a model originally proposed 
by Ganther[3]. This model is generally accepted although not all steps have been verified. A 
version of the selenium metabolism model is shown in figure 1. 
 
The overall idea of the metabolism model is that all ingested selenium is metabolised into 
hydrogenselenide (HSe-). HSe- is then used for further incorporation into selenoproteins or into 
metabolic end products for excretion[3]. The metabolic steps leading to formation of HSe- however 
have not been established and neither HSe- nor the involved metabolites have been verified. 
 
The degree of bioavailability of selenium is species dependent and dependent of the nutritional 
source and on the selenium status of the subject[15].  Selenium bioavailability is often referred to 
as the ability to replete tissue selenium levels or as the activity of the selenoprotein glutathione 
peroxidase (GPx)[16]. In a review on the bioavailability of selenium from foods, Finley argues that 
other measures of selenium bioavailability that is not entirely related to selenium tissue levels or 
GPx activity may be relevant, for example as the ability to reduce cancer[16]. Despite the 
variability introduced due to the factors mentioned above, an overall bioavailability of all forms of 
selenium of 70-95 % was reported and selenium from all nutritionally relevant compounds is 
bioavailable[16]. 
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Selenium is specifically incorporated into selenoproteins as SeCys. SeCys residues are often key 
elements in selenoprotein functional sites. Selenium is also found in all other proteins, where it is 
unspecifically incorporated as SeMet in competition with the sulphur analogue methionine as the 
organism is not able to distinguish between these amino acids[17,18]. Opposed to SeCys, SeMet is 
not crucial for protein activity. As the body is able to use selenium from SeMet to synthesize SeCys 
for incorporation into selenoproteins, it has been suggested that incorporation of SeMet into the 
general body proteins serves as a storage function for selenium[19].  
 
Selenium is excreted via urine or breath. The main urinary end product of selenium metabolism is 
now identified as an selenosugar: Se-methylseleno-N-acetylgalactosamine[20,21]. Two other 
selenosugars have been identified as minor urinary metabolites[22]. The trimethylselenonium ion 
Figure 1   Selenium metabolism scheme. A modified version of previously described models[2,3]. This 
scheme and all structures of the compounds mentioned in the scheme are presented in paper IV. Species 
in blue boxes have been verified by molecular mass spectrometry in biologically relevant samples. 
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(TMeSe) was formerly regarded as the main excretory species of excess selenium; however it has 
been shown that it is only a minor constituent in urine even after ingestion of large amounts of 
selenium. The controversial presence of TMeSe in urine has been thoroughly reviewed by 
Francesconi and Pannier[23]. Another end product of selenium metabolism is the volatile species 
dimethylselenide (DMeSe) which is excreted via the breath[24,25]. The end products seem to be 
common end products of selenium metabolism independent of ingested species.  
1.4 Aim and rationale of study 
Based on the above described selenium metabolism and cancer protection models it is evident that 
establishment of every step in selenium metabolism of nutritionally relevant selenium compounds 
is important as it may lead to a better understanding of the cancer protective effect. Metabolism of 
SeMet, Se-MeSeCys, selenocystine (SeCys2), selenite and MeSeA was investigated. Their structures 
are shown in figure 2.  
Se
O
-O
O- Se
O
OH
NH2
Se
Se
NH2
O
HO
O OH
NH2
Se
O
OH
Selenomethionine 
SeMet
Se-methylselenocysteine
Se-MeSeCys SelenocystineSeCys2
Selenite Methylseleninic acid
MeSeA
Se
OH
O
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The aim of this PhD project was to identify missing steps of selenium metabolism in order to asses 
the selenium species available for absorption. In vitro models of animal origin are easy and ethical 
to use and by choosing the right model metabolic findings are likely to be similar to in vivo human 
metabolic findings. Gastro-intestinal and hepatic models were chosen to elucidate initial steps in 
selenium metabolism as selenium is administered orally.  
 
An overview of the in vitro models and the investigated selenium compounds is given in table 1. 
 
 
 
Figure 2   Structures of selenium compounds investigated in this PhD project. 
 - 15 - 
 
Table 1  in vitro  models and the investigated selenium compounds
In vitro  model
Model for gastro-intestinal digestion Simulated gatric and 
intestinal juices 
Selenite, SeMet, 
SeCys2, Se-MeSeCys
Unpublished
Model for intestinal metabolism Intestinal epithelial cell 
homogenates (Pig)
Selenite, MeSeA, 
(SeMet, Se-MeSeCys)
Paper I and II
Model for hepatic metabolism Isolated hepatocytes (rat) MeSeA Paper III
Selenium compound investigated
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2 Analytical methods 
The analytical challenge in metabolism studies is related to the often very complex matrices of the 
samples and the low concentration of the metabolites of interest. The procedure of choice in 
bioinorganic speciation studies is a combination of hyphenated techniques such as liquid 
chromatography (LC) coupled with inductively coupled plasma (ICP) mass spectrometry (MS) and 
LC coupled with molecular MS[26].  
 
Although the coupling of LC with ICP-MS is not entirely straightforward[27], the combination of 
efficient separation of sample components and the good sensitivity offered by the element specific 
ICP-MS detector provides an excellent tool for detection of selenium containing compounds and LC-
ICP-MS is used through out this PhD project to screen samples for selenium metabolites. 
 
Molecular MS provides the structural information that is inherently lost upon LC-ICP-MS analysis. 
And from the beginning of this millennium it became the analytical approach of choice for 
elemental speciation to detect species by elemental analysis followed by structural identification of 
the detected species by molecular MS[28]. A thorough review of the use of molecular MS in 
speciation analysis was given by Rosenberg[29].  
 
The scope of paper IV was to give and overview of the selenium compounds related to selenium 
metabolism that was identified by the complementary use of element- and molecular specific mass 
spectrometry analysis. 
2.1.1 ICP-MS 
ICP-MS is often used as an element specific detector in selenium speciation studies. The use of 
ICP-MS for selenium detection was thoroughly reviewed by B´Hymer and Caruso[30].  
 
In ICP-MS the liquid sample is introduced into the instrument via a nebuliser and a spray chamber. 
The nebuliser provides an aerosol and the spray chamber ensures that only the smallest droplets 
reach the argon plasma. In the plasma, the droplets are desolvated, molecules are decomposed 
into atoms and finally the atoms are exited and ionized (figure 3). The ions are passed through the 
mass analyzer and detected based on their mass to charge ratio (m/z)[31]. As all molecules are 
decomposed to their atomic components no molecular structural data are obtained by ICP-MS. 
 
ICP-MS is considered a rather selective detector; however occurrence of spectral interferences 
compromises the selectivity. Spectral interferences are caused by atomic and polyatomic ions, 
formed in the plasma, with the same m/z as the ion of interest. Although selenium has six 
isotopes, all of them are subjected to interferences. The best known interferences on the selenium 
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isotopes are shown in table 2. The polyatomic interferences are caused by the plasma gas (argon) 
or atmospheric gases, the solvent or the matrix of the sample. The most abundant selenium 
isotope 80Se is severely interfered by the 40Ar40Ar+ dimer making this isotope practically useless to 
ordinary ICP-MS. In all ICP-MS analyses performed during this PhD project, the isotopes 77Se, 78Se 
and 82Se were measured simultaneously. Only the 82Se isotope is presented in the figures because 
this isotope resulted in the best signal-to-noise ratio. All three selenium isotopes were measured 
however in order to conclude, based on the relative isotope ratios versus the theoretical ones, 
whether a signal is specific to a selenium compound or due to an interference.  
 
Aerosol droplets
A(H2O)+X-
Molecules
AX
Atoms
A
Ions
A+
Particles
(AX)n
DesolvationVaporizationDecompositinIonization
courtesy of Lars Bendahl
 
 
Isotope Abundance (%) Interferences
74Se 0.89 37Cl2
+, 40Ar34S+
76Se 9.36 36Ar40Ar+, 38Ar38Ar+, 40Ar36S+, 31P2
14N+
77Se 7.63 40Ar37Cl+, 40Ar36Ar1H+
78Se 23.78 38Ar40Ar+, 31P2
16O+
80Se 49.61 40Ar2
+, 1H79Br+
82Se 8.73 12C35Cl2
+, 34S16O3
+, 82Kr+, 40Ar2
1H2
+, 1H81Br+
Table 2   Relative abundances and some interferences on selenium isotopes
 
Although the sensitivity of selenium with argon ICP-MS is considered poor it is still very sensitive 
compared to ESI-MS. For most selenium compounds the sensitivity of ICP-MS is often 2-3 orders of 
magnitude higher than the sensitivity of electrospray ionisation (ESI)-MS[26]. Typical detection 
Figure 3   Ionization processes in the argon plasma of the ICP-MS 
 - 19 - 
limits for selenium in ICP-MS quadrupole instruments are 10-100 ppt. This is an average sensitivity 
as elemental detection limits covers the range of less than 1 ppt to more than 10 ppb. Only a few 
elements are not suitable for ICP-MS detection[32]. The sensitivity of selenium is influenced by the 
high 1st ionization potential leading to a degree of ionization of only 30%[33]. The sensitivity of 
selenium is also influenced by other matrix interferences that are not spectral interferences. These 
interferences may result in either enhancement or reduction of the selenium signal and they are 
greatly influenced by the operating conditions of the plasma[32]. Hence, selenium standards in the 
mobile phase were used for optimization of ICP-MS operating conditions.  
 
Sensitivity with respect to the detection limit of selenium was not an obstacle in this PhD project as 
the limit of detection for the ICP-MS detector was far lower than the limit of detection for the ESI-
MS detector used for molecular identification. However, it is well known that selenium sensitivity 
can be enhanced by addition of carbon-containing solutes such as methanol to the mobile phase. 
Even small concentrations of organic solvent have a significant effect on selenium signal 
enhancement[34]. High concentrations of organic solvents however will extinguish the plasma. The 
amount of organic solvent entering the plasma can be reduced by cooling the spray chamber. 
Therefore, the spray chamber was kept at 5° C whenever methanol concentration above 5 % in the 
mobile phase was required for optimal chromatographic conditions. 
2.1.2 ESI-MS (positive mode) 
Molecular MS provides the structural information that is inherently lost in ICP-MS. Identification of 
selenium containing compounds by molecular MS is facilitated by the characteristic isotope pattern 
of selenium that is easily recognized. The characteristic isotope pattern for molecules containing 
one or two selenium atoms are shown in figure 4.  
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Figure 4   Calculated isotope patterns for A) a selenium compound containing one selenium atom 
represented by dimethylselenide and B) a selenium compound containing two selenium atoms represented 
by dimethyldiselenide (paper IV). 
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Since electrospray ionization is possible for a wide range of molecular masses and analyte 
polarities and it is relatively simple to use, it is often the ionization technique of choice in speciation 
analysis. An electrospray is produced by applying a strong electric field to a solution that is passed 
through a spray capillary. The electric field induces a charge accumulation at the surface of the 
solution located at the end of the capillary. The highly charged surface will break the solution into 
highly charged droplets i.e. an electrospray[35] (figure 5). The droplets are evaporated by a 
combination of heat and a stream of an inert drying gas, which causes them to shrink to the point 
where the repulsive power between the positively charged ions make the droplets break up into 
smaller droplets. This process will continue until at some point desorption of ions from the droplet 
surface occurs[35]. In principle the molecular ion of the analyte; M+ is formed, however in the 
positive mode most often ions are formed by addition of a proton from the mobile phase, which 
results in protonated ions; [M+H]+. 
 
+
+
+
+
+
-
M 
M 
M 
M 
M 
- 
- 
- 
- 
High voltage 
power supply 
 M +
+
+
+
+
 M +
+
+
+
+M M 
 +
+
M 
 
+
+M 
+
M +
M +
Electrons 
+ -
 
 
The softness of the ionization process generates ions in the gas phase which are very similar to the 
ions in the liquid phase as opposed to the ICP-MS ionization process. However collision with the 
drying gas may lead to a varying degree of fragmentation[29]. This so called insource 
fragmentation is relevant to minimize as it results in poorer sensitivity when the analyte signal is 
split up. The interface parameters are to be optimized to obtain complete desolvation of the ions 
without compromising their integrity.  
 
One major disadvantage of the ESI technique is that it is highly prone to matrix interferences 
resulting in poor or lack of sensitivity to sample components of interest; to sustain the 
electrospray, electrochemical reactions take place in the tip of the spray capillary. As a 
consequence the total number of ions that can be extracted from the spray capillary is limited by 
the electric current produced by these electrochemical reactions, hence presence of interfering 
Figure 5   Schematic representation of the ionization process in ESI-MS (Positive mode) 
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compounds that are more prone to ionization may partly suppress the ionization efficiency of the 
analyte resulting in poor sensitivity. Furthermore, the electrospray droplets have to be completely 
desolvated in order for the ions to enter the mass spectrometer. The use of volatile solvents is 
therefore preferred and better sensitivity is often obtained with high concentrations of methanol or 
acetonitril that unfortunately are incompatible with ICP-MS.  
 - 22 - 
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3 Experimental 
3.1 Instruments 
LC-ICP-MS 
The ICP-MS was a PE Sciex Elan 6000 (Perkin Elmer, Norwalk, CT, USA) equipped with a Micro Mist 
glass concentric nebulizer (Glass Expansion, Romainmontier, Switzerland)  and a PC3 cyclonic 
spraychamber (Elemental Scientific Inc., Omaha, NE, USA). The sample uptake rate was 200 µL 
min-1. ICP-MS sampler and skimmer cones were made of platinum. The plasma and auxiliary gas 
flow rates were 15 L min-1 and 1.2 L min-1, respectively. The nebuliser gas flow, lens voltage and 
ICP RF power were optimized regularly with a solution of 100 μg Se L-1 in mobile phase. The data 
requisition settings were: dwell-time 500 ms, sweeps per reading 1 and readings per replicate were 
varied corresponding to chromatographic runtime. 77Se, 78Se and 82Se isotopes were monitored. 
The LC instrument was a G1376A capillary pump, a G1313A autosampler, a G1316A column 
compartment, a G1379A degasser and a G1314A variable wavelength detector, all from Agilent 
1100 series, controlled by ChemStation software (Agilent Technologies, Waldbronn, Germany). 
 
LC-ESI-MS (ion trap) 
The ESI-MS ion trap detector was a G2445 LC/MSD Trap equipped with an API-electrospray 
interface (Agilent) controlled by LC/MSD Trap software (Bruker Daltronics Inc.) used for data 
acquisition and processing. The ESI-MS was coupled to a LC system consisting of a G1322A 
degasser, a G1312A binary pump, a G1315B diode array detector, a G1316A column compartment 
and a G1313A autosampler (all from Agilent). The electrospray was produced in the positive 
ionization mode. Details of the electrospray parameters are given in papers I-III. 
 
LC-ESI-MS (triple quadrupole) 
The ESI-MS triple quadrupole detector was a Thermo Finnigan TSQ Quantum Utra AM triple 
quadrupole mass spectrometer with a ESI interface coupled to a Thermo Finnigan Surveyor LC 
system (Thermo Fisher Scientific, Waltham, MA, USA). The electrospray was produced in the 
positive ionization mode. Details of the electrospray parameters are given in paper III. 
3.2 Procedures 
Unless otherwise stated the following procedures were applied. 
 
Chromatography 
 All LC-ICP-MS analysis were performed with two Luna C18(2), 3µ, 100Å, 2 mm ID × 100 mm 
(Phenomenex, SupWare, Denmark) columns in series at ambient temperature unless otherwise 
stated in the figure legend. The flow rate was 200 µL min-1. The mobile phase consisted of 200 
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mmol L-1 ammouniumacetate in 5 % methanol unless otherwise stated in the figure legend. 12 µL 
sample aliquots were injected. UV detection was performed at 214 nm. 
 
Digestion in simulated intestinal fluid (SIF) 
SIF was freshly prepared and consisted of 10 mg ml-1 pancreatin in 50 mmol L-1 potassium 
phosphate buffer pH 6.8. Standards of SeMet, SeCys2, Se-MeSeCys and selenite were digested at 
37° C for 24 h under constant rotation. The concentration of selenium in the digestion samples 
were 1 mg L-1. Digestion was terminated by protein precipitation with trichloroacetic acid in a final 
concentration of 2 %. The samples were filtered before subjected to LC-ICP-MS analysis. The 
standards were also incubated in the potassium phosphate buffer without enzyme.  
 
In vitro digestion (IVD) 
Selenium standards were incubated in pepsin 50 mg ml-1 in 50 mmol L-1 hydrochloric acid for 1 h at 
37° C under constant stirring. This mimics gastric digestion. Hereafter pancreatin was added to a 
final concentration of 7.5 mg ml-1 and sodium taurocholate was added to a final concentration of 5 
mg ml-1. Finally, pH was adjusted to approximately 6.5 with sodium hydrogencarbonate. The 
samples were further incubated at 37° C under constant stirring for 1 h. These conditions mimic 
the digestion in the proximal jejunum. After 1 h, sacks of tied off dialysis tube (cutoff Mw<5000) 
containing water was added to the digestion sample and digestion was allowed to proceed another 
4 h under concurrent dialysis. Standards of SeMet, SeCys2, Se-MeSeCys and selenite were digested 
at a final selenium concentration of 10 mg L-1. The content of the dialysis sacks were analysed by 
LC-ICP-MS. For comparison the standards were incubated under similar conditions except that 
none of the enzymes pepsin and pancreatin were present. 
 
In vitro intestinal metabolism 
The small intestine from a pig was slit longitudinally and rinsed with ice-cold isotonic phosphate 
buffer (50 mmol L-1 potassium dihydrogen phosphate and 90 mmol L-1 sodium chloride adjusted to 
pH 7.4). The mucosal cells were scraped from the underlying muscle layers with a glass slide. The 
cells were suspended in isotonic phosphate buffer in a concentration of 20% w/w and homogenized 
with a Heidolph DIAX 600 homogenizer (VWR International, West Chester PA, USA) for 0.5 min. 
The homogenates were stored at -18o C. Standards of SeMet and Se-MeSeCys were incubated at 
37° C for 24 h under constant rotation. The concentration of selenium in the incubation samples 
were 5 mg L-1. Details of the incubation of selenite and MeSeA in intestinal epithelial cell 
homogenates are described in paper I and II, respectively. Incubation was terminated by protein 
precipitation with trichloroacetic acid in a final concentration of 2 % followed by centrifugation at 
5300 rpm for 15 min. The supernatant was filtered through a 0.45 μm syringe cellulose filter 
before LC-ICP-MS analysis.  
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Hepatic metabolism (hepatocytes) 
Hepatocytes were isolated from Sprague Dawley rats (150-200 g) obtained from Charles River 
Laboratories (Sulzfeld, Germany). The isolation was performed according to the two-step perfusion 
model described by LeCluyse et al. [36] and cryopreserved as described by Le Cam et al. [37]. 
Isolated hepatocytes were suspended in Dulbecco´s modified Eagle´s medium containing 10 % 
dimethyl sulfoxide. The suspension was immediately frozen at -20°C for 20 min followed by one 
hour storage at -80°C before storage in liquid nitrogen. Upon thawing, cryopreserved hepatocytes 
were suspended in Dulbecco´s modified Eagle´s medium. Cell viability was determined by the 
trypan blue exclusion method. At the end of the incubation periode, the cells were separated from 
the medium by centrifugation at 4000 g for 5 min. The incubation medium was analyzed directly, 
while the cell pellet was treated with acetonitrile. Acetonitrile extract was evaporated under a N2 
stream. The residue was sonicated after addition of a solution of 20 mmol L-1 ammonium acetate in 
2 % methanol. This fraction was separated by centrifugation 1000 g for 5 min and the supernatant 
was analyzed. The remaining pellet was solubilised in 5 % sodium dodecyl phosphate by 
sonification prior to total selenium analysis. All samples were stored at – 20°C until analysis. Total 
selenium analyses were performed by flow injection 82Se-ICP-MS using the standard addition 
method.  
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4 Results and discussion 
In this thesis the metabolism of selected selenium species were investigated in simulated 
gastrointestinal fluids, in an intestinal and in a hepatic model. Published results and unpublished 
results are presented and discussed collectively.  
4.1 Gastro-intestinal digestion (unpublished results) 
In order to examine if selected selenium compounds were changed during passage of the 
gastrointestinal tract, studies in simulated intestinal fluid[38] (SIF) were performed (results not 
published). SIF was freshly prepared and consisted of 10 mg/ml pancreatic enzyme in phosphate 
buffer pH 6.8. Standards of SeMet, SeCys2, Se-MeSeCys and selenite were digested at 37° C for 24 
h under constant rotation. Digestion was terminated by protein precipitation and the samples were 
filtered before subjected to LC-ICP-MS analysis. The standards were also incubated in the 
phosphate buffer without enzyme. SIF was prepared according to the US pharmacopoeia[38] in 
which it is primarily used for dissolution tests of enteric coated solid dosage forms. It contains the 
proteolytic enzyme pancreatin and has the salinity and pH of the duodenum and the proximal 
jejunum.  
 
Se-MeSeCys was not stable in buffer which resulted in reduction of the Se-MeSeCys peak area in 
the LC-ICP-MS chromatograms. No additional digestion of Se-MeSeCys was observed when the 
enzyme was present (figure 6A). SeMet was stable in buffer and was not digested by the enzyme 
in SIF (figure 6B). Selenite was stable in the buffer but when subjected to SIF digestion selenium 
disappeared (figure 6C). Selenium from selenite was probably volatilised or associated to the 
insoluble protein fraction of the incubation sample. Results of repeated incubations of SeCys2 were 
inconsistent, hence no reliable results was obtained for this species.  
 
The selenium standards were also investigated in an In vitro digestion model (IVD), originally 
developed to investigate protein interactions with intestinal absorption of inorganic iron[39]. This 
model includes simulated gastric digestion for 1 hour before introduction of simulated intestinal 
digestion conditions for 4 hours. Digestion was followed by dialysis which allowed passing of small 
molecules. Standards of SeMet, Se-MeSeCys, SeCys2 and selenite were incubated.  
 
No digestion and no loss of selenium species was observed in the dialyzed samples compared to 
samples treated in the same way except that no enzymes were present during incubation.  This is 
not in consistency with the results of SIF digestion; SeMet was not changed in any of the models 
but Se-MeSeCys and selenite underwent some transformation in SIF. 
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The SIF and IVD models are inherently rather similar. The models differ only in that the IVD model 
in addition to the pancreatic enzyme also contains a gastric enzyme and bile salts and they differ in 
incubation time. The different results obtained in the two models may be due to the different 
incubation time; In SIF standards was digested for 24 h and in the IVD model gastric digestion 
occurred for 1 hour followed by 5 h intestinal digestion. Impact of incubation time was not further 
investigated. However, it could be argued that long gastric digestion is irrelevant as the ventricle 
will be emptied in 4 hours after a meal is ingested. 7-8 hours post ingestion; indigestible remains 
of a meal have passed the intestine and reached the colon. In the colon very few species in general 
are able to be absorbed[40]. Hence, species that are not digested during 8 h may either be 
absorbed in their original form or excreted via faeces and thereby not systemic available.  
 
Figure 6   LC-ICP-MS analysis of simulated intestinal fluid incubations of A) Se-MeSeCys , B)SeMet with 
their respective undigested samples in black and C) selenite. Chromatographic conditions as described in 
the experimental section. All chromatograms in A and B are off scale by 2000 cps. 
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Regarding the selenoamino acids our results are in concordance with the results of Dumont et 
al[41] who concurrently published similar studies in simulated gastric and intestinal juices. They 
also found that no further digestion of SeMet and Se-MeSeCys appeared to take place. They 
recovered 95-100 % of the dosed selenium of selenite by flow injection analysis of the digested 
sample which indicates that selenium of selenite is associated to the insoluble fraction. However 
Dumont et al did not report whether any digestion of selenite was observed.  The main aim of the 
studies by Dumont et al was to assess which species were produced during gastrointestinal 
digestion of selenized yeast[41] and selenized garlic[42]. The main digestion products of selenized 
yeast were SeMet and SeCys2. Digestion products of garlic were SeMet, Se-MeSeCys and γ-
glutamyl-methylselenocysteine. However they reported that γ-glutamyl-Se-methylselenocysteine 
was extensively digested in the gastrointestinal fluids leaving Se-MeSeCys as the major digestion 
product of selenized garlic. Also Reyes et al[43] identified SeMet as a major digestion product of 
selenized yeast. However they also presented Se-containing peptides that was randomly produced 
by the gastrointestinal enzymes. It is very likely that these fragments of incompletely digested 
proteins contain selenium as selenomethionine. Whether these Se-containing peptides are relevant 
for absorption depends largely on their size or whether they are transported by peptide carriers in 
the gastrointestinal tract[44]. 
 
In conclusion, the digestion experiments showed that the selenoamino acids SeMet and Se-
MeSeCys were not decomposed by the pancreatic and gastric enzymes, whereas selenite may be 
extensively decomposed into species that is not detectable by LC-ICP-MS analysis. Therefore no 
further digestion studies were performed. Based on the digestion studies it was concluded that 
SeMet, SeCys2 and Se-MeSeCys were relevant model compounds for intestinal metabolism studies. 
Although it was not conclusive whether selenite was digested based on the two models, selenite 
was also subjected to intestinal metabolism studies. 
4.2 Intestinal metabolism  
Selenium metabolism was studied in homogenised pig intestinal epithelial cells as a model for 
intestinal metabolism. MeSeA was included as it has been widely used in cancer research as a 
model compound for methylated Se-amino acids, in particular Se-MeSeCys.  
 
The results of the intestinal metabolism studies of selenite and MeSeA are published in papers I 
and II, respectively, whereas the results of incubations of SeMet and Se-MeSeCys are unpublished. 
For this model the intestine from anaesthetized pigs was removed, slit longitudinally and rinsed. 
The mucosal and epithelial cell layers were scraped of the underlying muscles layers, suspended 
and homogenised in saline phosphate buffer. The homogenates contains epithelial cells, their 
contents and intestinal mucosa. Selenium standards were added and incubated at 37°. Protein and 
cellular membrane residues were precipitated and the soluble fractions were analysed for 
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appearance of metabolites. The analysis for metabolites was limited to the soluble fraction, and did 
not include volatile or precipitated metabolites.  
 
Epithelial cell homogenates like tissue homogenates provides data on intestinal metabolism 
pathways. However, extrapolation to in vivo conditions might be compromised by differences in 
model animal and human enzymes and their abundance[45,46]. As it was not known which 
enzyme pathways that would be involved in metabolism of the selenium compounds the epithelial 
cell homogenates were not standardized to a specific biological activity. It was found that the 
principal conversion of the selenium compounds was spontaneous and did not require enzymatic 
activity and therefore, the homogenates were not further characterized. 
4.2.1 Selenoamino acids (unpublished results) 
Extensive conversion of the selenoamino acids appeared as they were only recovered in limited 
amounts in the soluble fraction after incubation. However, only small amounts of metabolites of 
SeMet and Se-MeSeCys were observed in the soluble fraction (figure 7). Results from different 
epithelial cell homogenates from different pigs, differed quantitatively in the rate of disappearance 
and also to smaller extent qualitative differences were observed. The epithelial cell model is not 
well characterized and variation in the metabolic enzyme panel and enzyme amounts may account 
for different findings in different animals and epithelial cell homogenate batches. The epithelial cell 
homogenates may also be altered upon storage and this could cause different outcome of 
incubations too. 
 
Although the metabolites of SeMet and Se-MeSeCys were not identified, LC-ICP-MS analyses of the 
respective samples indicate that the species may have at least two common metabolites observed 
at retention time 7.9 min and 16.5 min in the chromatograms. The broad peak eluting at 14-20 
min is increased background due to increasing methanol content in the mobile phase. Several 
selenium containing compounds were strongly retained by the column; hence this experiment 
stresses the need for gradient elution with larger amounts of organic solvents, which make ICP-MS 
detection troublesome.  
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According to these results, SeMet and Se-MeSeCys may be metabolised by intestinal epithelial cells 
and delivered to the body in another form. However, the standards were incubated with the 
epithelial cell homogenates for 24 h, which is much longer than the intestinal transition time in 
vivo. No further experiments on SeMet and Se-MeSeCys intestinal metabolism were performed. 
4.2.2 Selenite (paper I) 
When selenite was incubated with homogenized epithelial cells, two major selenium containing 
compounds were observed in the soluble fraction. Minor selenium containing compounds were 
observed in the void volume (figure 8). This could be excess selenite or other hydrophilic 
compounds not retained by the column. The two compounds were formed instantaneously and they 
were very labile as the amount declined during a 15 min period. No other selenium containing 
peaks appeared instead. Hence, the secondary reaction products were volatile or precipitated. The 
primary compounds were stabilised by acidification which made them stable enough for further 
handling. The identity of the compounds was tentatively identified as the selenotrisulfide of 
glutathione (GSH) and the mixed selenotrisulfide of GSH (GS-Se-SG) and cysteine (GS-Se-Cys), 
Figure 7   Soluble fraction of intestinal metabolism study of SeMet (top, offset by 15000 cps) 
and Se-MeSeCys (bottom). Mobile phases; A) 0.1 % formic acid in 2 % methanol and B) 0.1 % 
formic acid in 50 % methanol. Gradient; 0-15 min linear from 0-100 % B followed by 
equilibration in 0 % B. 
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respectively as their retention times were identical when spiked with standards of the 
selenotrisulfides.   
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A selenium rich sample was prepared, in order to obtain the selenotrisulfides in concentrations 
suitable for detection by LC-ESI-MS. Based on retention time matching with the ordinary sample, 
the same selenotrisulfides were observed irrespective of the amount of selenite incubated. LC-ESI-
MS spectra of the tentatively assigned selenotrisulfide peaks in the sample and LC-ESI-MS spectra 
of selenotrisulfide peaks in the standard were similar except for the presence of sodium and 
potassium adducts in the intestinal sample (figure 9).  
 
Standards of the selenotrisulfides were prepared simply by mixing an aqueous solution of GSH and 
Cys with an acidified solution of selenite, hence formation of selenotrisulfides does not require any 
metabolic enzymes and they are formed instantaneously whenever selenite and GSH and/or Cys 
are present at the same time. Nevertheless, the selenotrisulfides are metabolically important as 
the thiols are ubiquitously present through out the gastrointestinal tract[47].  
 
The formation of GS-Se-Cys and GS-Se-SG has never been identified by LC-ESI-MS in intestinal 
models before. Experiments of the absorption of selenite in models of rat intestine have shown that 
Figure 8   Intestinal metabolism of selenite (black) spiked with a mixture of selenotrisulfide standards 
(blue). Mobile phases; A) 0.1 % formic acid in 2 % methanol and B) 0.1 % formic acid in 50 % 
methanol. Gradient; 0-30 min linear from 0-100 % B followed by equilibration in 0 % B. (paper I) 
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the presence of GSH increased cellular accumulation of 75Se-labelled selenite[48] and that uptake 
of GS-Se-SG and Cys-Se-Cys was ten times faster than for selenium in the form of selenite[49]. 
The presence of selenite, GS-Se-SG, GS-Se-Cys, Cys-Se-Cys and protein-bound selenium in 
perfusates of the intestinal lumen of the rat has been proposed[50]. Identification of the 
selenotrisulfides in all of these experiments was based on unspecific 75Se measurements or co-
elution with standards in different chromatographic systems. Braga et al[51] showed formation of 
Cys-Se-Cys and GS-Se-SG in homogenized livers of rats injected intraperitoneal with selenite. The 
identification of the selenotrisulfides was based on co-elution with standards. The identity of the 
standards was established by LC-ESI-MS.  
 
506.9
528.9
544.8
0.0
0.5
1.0
1.5
x104
Intens.
400 420 440 460 480 500 520 540 560 580 m/z
[Cys-Se-SG + H]+
[Cys-Se-SG + Na]+
[Cys-Se-SG + K]+
693.0
714.9
730.9
0
2
4
6
x104
Intens.
600 620 640 660 680 700 720 740 760 780 m/z
[GS-Se-SG + H]+
[GS-Se-SG + Na]+
[GS-Se-SG + K]+
0.0
0.2
0.4
0.6
0.8
1.0
Intens.
0.0
1.0
2.0
3.0
4.0
5.0
Intens.
691.3
693.0
694.9
x105
670 680 690 700 710 m/z
[GS-Se-SG + H]+
690.3
689.3
685 690 695 U
R
el
at
iv
e 
In
te
ns
ity
505.0
506.9
508.8
x106
480 490 500 510 520 m/z
[Cys-Se-SG + H]+
504.1
503.1
500 505 510 UR
el
at
iv
e 
In
te
ns
ity
A B
R
el
at
iv
e 
In
te
ns
ity
R
el
at
iv
e 
In
te
ns
ity
R
el
at
iv
e 
In
te
ns
ity
R
el
at
iv
e 
In
te
ns
ity
R
el
at
iv
e 
In
te
ns
ity
R
el
at
iv
e 
In
te
ns
ity
R
el
at
iv
e 
In
te
ns
ity
R
el
at
iv
e 
In
te
ns
ity
R
el
at
iv
e 
In
te
ns
ity
R
el
at
iv
e 
In
te
ns
ity
 
 
Selenotrisulfides of other biological relevant thiol compounds such as Coenzyme A[52,53], 2-
mercaptoethanol[52], reduced ribonuclease A[54], homocysteine[51], dihydrolipoic acid[53], 
mercaptoethylamine[55] and cysteine[55] have been synthesized in aqueous solution. Some for 
reaction mechanism studies and others as standards for chromatographic retention time 
Figure 9   Intestinal metabolism of selenite. A) mass spectra of tentatively assigned selenotrisulfide 
peaks and B) mass spectra of standard selenotrisulfide peaks with same retention time. The inserts 
represent calculated isotope distributions of the proposed selenotrisulfides. Chromatographic 
conditions as in figure 8. (paper I) 
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comparison and mass spectrometry. The selenotrisulfides of mercaptoethylamine[55] and 
cysteine[51,55,56] have been detected in biological samples. However their physiological relevance 
has not been elucidated. Our investigation of selenite metabolism in intestinal epithelial cell 
homogenates indicates that besides GS-Se-SG also substantial amounts of the mixed 
selenotrisulfide Cys-Se-SG most certainly are formed in vivo. Hence, besides investigations of GS-
Se-SG, further research in selenite absorption and metabolism pathways must include other 
selenotrisulfides, at least the selenotrisulfides of cysteine; Cys-Se-SG and Cys-Se-Cys. 
 
Selenotrisulfides are well known reaction products of selenite and thiol compounds and during the 
last century this reaction was thoroughly investigated for stoichiometry and reaction mechanism. 
Still, questions about the reaction in relation to physiology are unresolved. Painter reviewed 
selenium chemistry and toxicity in 1941 and reported the reduction of seleninic acid by thiol 
compounds[57]. In the late 1960´s and early 1970´s Ganther published several papers on 
selenotrisulfide studies suggesting the series of reduction reactions most referred to hereafter 
(figure 10) [1,52,58].  
+4 H2SeO 3 +  4 GSH
GSSeSG +   GSSG  +3 H2O
0       GSH   +   Se  GSSeH GSSe-CH2COOH + HI
-2 CH3-Se-CH3
(1)
TPNH
gluthatione
reductase
TPN+
(2a) (2b)
GSH
(excess)
GSSG
I-CH 2COOH
S-adenosyl-
m ethionine
(3) (4)
H2Se
+2
Sum mary of the reductive Metabolism of Selenium a
a Reactions 1-4 are established with reasonable certainty. The further
m etabolism of selenium to the -2 oxidation state with ultim ate m ethylation
is known to occur but the pathway involved is not established
 
 
Figure 10   This diagram was presented by Ganther in 1971[1]. The footnote a is somewhat 
still true. 
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With enzymatic techniques, Kramer and Ames[59] further integrated formation of the superoxide 
anion in the reaction scheme. At the same time Vendeland et al published molecular mass spectra 
of GS-Se-SG and Cys-Se-Cys in aqueous solution[49] and later Braga et al published mass spectra 
of Cys-Se-SG and the selenotrisulfide of homocysteine (HCys-Se-HCys) standards[51].  
 
The reductive metabolism of selenite produces intermediate species i.e. HSe- and perselenides (R-
SeH), that are highly reactive or volatile, hence positive identification of all involved species 
imposes serious analytical challenges. Spontaneous formation of the proposed intermediate 
perselenide (GS-SeH) was shown by Ganther[1] as the reaction product of iodoacetate. The 
identification of the derivative (GS-Se-acetate) was based on retention time shifts in 
electrophoretic and chromatographic systems. However GS-SeH has never been isolated and 
identified as such, probably because it is far too reactive to be stable in solution. Formation of the 
volatilized HSe- has been concluded by loss of selenium from reaction mixtures upon acidification. 
The relative quantity of HSe- formation has not been reported. Formation of elemental selenium is 
reported based on visual observation of red precipitate in reaction mixtures or by measuring the 
absorbance at wavelength 400 nm. Today this kind of analytical evidence is considered obsolete. 
Nevertheless, despite great technical advances the quote “The further metabolism of selenium in 
the -2 oxidation state with ultimate methylation is known to occur but the pathway involved is not 
established” of Ganther from 1971 is still somewhat true.  
 
The formation of GS-Se-SG is well established and the compound has been identified by molecular 
MS in aqueous standards[49,51], in aqueous yeast extracts[56] and now in intestinal epithelial cell 
homogenates. The LC-ICP-MS analysis of the aqueous GS-Se-SG standard revealed an additional 
minor peak (figure 11). LC-ESI-MS analysis revealed a spectrum with the characteristic isotope 
pattern of a compound containing two selenium atoms at m/z 772.4 for the 80Se80Se compound 
(figure 11). The spectrum is similar to the theoretically calculated isotope pattern of 
diselenodiglutathione (GS-Se-Se-SG). This compound has never been reported as part of the 
reductive reaction cascade of selenite and GSH (unpublished results).  
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As glutathione is widely present throughout the animal and human bodies the most important 
selenotrisulfide is considered to be selenodiglutathione (GS-Se-SG). GS-Se-SG is essentially 
unstable at physiological conditions i.e. pH approximating neutral and GSH excess. In the stomach, 
the selenotrisulfides may be stable because the pH is low, but in the intestine where pH reaches 
neutral, the selenotrisulfides are most certainly unstable. The in vivo fate of the selenium from the 
rapid decomposition of the selenotrisulfides has been widely speculated and discussed, but no clear 
evidence for a specific metabolic pathway has been provided. Ganther proposed that in addition to 
the spontaneous reduction of selenite by GSH the reduction was enhanced by action of the enzyme 
Glutathione Reductase (GR) to yield diglutathione (GS-SG) and HSe- (figure 12). GR is a 
ubiquitously present enzyme that reduces diglutathione to glutathione using redox equivalents 
from NADPH[1].  
Figure 11   LC-ICP-MS and LC-ESI-MS analysis of an aqueous mixture of GSH and selenite. 
Chromatographic conditions as in figure 8. 
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The reactive and toxic intermediate HSe- is often referred to as the key intermediate in selenium 
metabolism available for selenium incorporation into proteins and for excretion via methylation. In 
biological material, formation of red elemental selenium (Se(0)) has not been reported suggesting 
existence of biological mechanisms that prevent the formation of Se(0). Rapid methylation or 
incorporation into selenoproteins via selenophosphate may be one mechanism. Another proposed 
fate of the selenotrisulfides is that selenium is directly donated to sulfhydryl groups of proteins. 
The rationale for this mechanism would be that the cell avoids free HSe- which is highly toxic[60]. 
Incorporation of selenium into selenoproteins takes place via a specific translational codon for 
selenocysteinyl-tRNA. Selenocysteinyl-tRNA is synthesized via selenophosphate.  Selenophosphate 
is synthesized by selenophosphate synthetase (SPS) as shown in figure 13. SPS is claimed to have 
HSe- as the selenium donating substrate and adenosinetriphosphate (ATP) as the phosphate 
donating substrate[61,62]. 
 
ATP  +  HSe-  +  H2O 
Selenophosphate 
synthetase 
Selenophosphate  +  Pi  +  AMP 
 
Figure 12   Reactions mediated by glutathione reductase (GR)[1]. Reaction C has never been 
investigated and it is highly speculative. 
 
Figure 13    Reaction mechanism of selenophosphate synthetase (SPS)[49] 
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HSe- is claimed to be produced in situ by the reduction of selenite. Whether selenite is reduced to 
HSe- or it is the intermediate reduction products that are substrates for selenophosphate 
synthetase has not been proven; however the reduction of selenite is pre-requisite for any 
incorporation of selenite selenium into selenophosphate[62,63].  
 
In conclusion, although our in vitro intestinal metabolism studies of selenite have not added any 
further evidence for pathways of selenite metabolism, they emphasize the fact that selenite is 
reduced intestinally and will never be bioavailabe in its intact form. What is really missing is the 
identity of the form in which selenium of selenite origin is absorbed from the intestine.  
4.2.3 Methylseleninic acid (paper II) 
MeSeA was first introduced as a model compound for selenoamino acids by Ip et al[64] in 2000 
and as it is not naturally occurring it had gained limited interest in metabolism research until then. 
Se-MeSeCys is believed to produce MeSeH when cleaved by the β-lyase enzymes and MeSeA is 
believed to produce MeSeH by a series of spontaneous reductions by thiols such as Cys and 
GSH[2] (figure 14). Hence, MeSeA has been widely used in cancer research as a precursor for 
MeSeH in studies performed both in vitro and in vivo to ensure formation of MeSeH despite low β-
lyase activity in target tissue or in vitro models[2,64-68]. 
 
Se-MeSeCys 
β-lyase 
Alanine  +  MeSeH 
MeSeA  +  GSH Spontaneous S-(MeSe)-SG Spontaneous MeSeH 
2 R-SH RS-SR + H2O R-SH GS-SR 
 
 
In our studies, MeSeA was extensively metabolised when incubated with homogenized epithelial 
cells and one major selenium containing compound (A) was observed in the soluble fraction. The 
compound was formed immediately after addition of MeSeA to the cell homogenate. In contrary to 
the selenotrisulfides identified when selenite was added to the cell homogenate, this compound 
remained present in the soluble fraction even after 24 h incubation. However, not all of the 
selenium applied to the column could be accounted for and analysis of the sample by use of 
gradient elution revealed another selenium containing compound (B) in the soluble fraction (figure 
15). The size of this peak varied in between incubations. In addition, the relative peak sizes were 
not comparable as the ICP-MS sensitivity is greatly influenced by the changing methanol content of 
the mobile phase in gradient elution, making quantitation of the compounds difficult. 
Figure 14   Reactions leading to formation of methylselenol (MeSeH)[55] 
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The sample was subjected to LC-ESI-MS, but no peaks with a spectrum with the characteristic 
selenium isotope pattern were observed at the retention times of the unknown compounds. 
Following, the sample was purified by preparative chromatography in two different mobile phases. 
The mobile phases contained 0.1% formic acid (pH 2.6) and 0.1% ammonium formate (pH 7), 
respectively. The fractionation on the preparative column was monitored by splitting the flow and 
continuously monitoring the selenium output by ICP-MS in order to collect the relevant fraction. 
The retention time of the metabolite did not change in the different systems, but from the UV-trace 
(not shown) it appeared that the purity of the metabolite increased by separating the metabolite 
from different impurities in the two systems. The purified sample was analysed by LC-ESI-MS and 
a peak with a spectrum containing the characteristic selenium isotope pattern was observed at the 
retention time of the major selenium containing metabolite (A)(figure 16). Purification and pre-
concentration of the other selenium containing metabolite (B) was not successful.  
Figure 15   Intestinal metabolism of MeSeA (offset by 1000 cps). Mobile phases; A) 0.1 % 
formic acid in 2 % methanol and B) 0.1 % formic acid in 50 % methanol. Gradient; 0-10 min 
100% A, 10-30 min  linear gradient to 100 % B, 30-35 min 100 % B. (paper II) 
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The characteristic isotope pattern of selenium was identified at m/z 126.9, m/z 198.8 and m/z 
215.9 corresponding to 80Se. The ion at m/z 215.9 [CH3SeCys+H]+ is the parent ion, but due to 
excessive in-source fragmentation, the ion at m/z 198.8 is the most intense. A small signal with a 
selenium pattern was identified at m/z 237.9, which corresponds to the sodium adduct of m/z 
215.9. Full scan spectra were recorded in the m/z range 150-800 to examine if the ion was a 
fragment ion, produced by in source fragmentation of a larger ion. However, no selenium isotope 
pattern was observed above m/z 250. Based on these data, the identity of the metabolite was 
expected to be the sulfur-selenium amino acid S-(methylseleno)cysteine (S-(MeSe)Cys). As this 
compound resembled the selenotrisulfide of cysteine (Cys-Se-Cys) (figure 17) except that selenium 
only coordinates with one sulphur, while the methylseleno group is preserved, it was investigated 
whether addition of an aqueous solution of MeSeA to Cys would produce the metabolite.  
Figure 16   LC-ESI-MS spectra of A) purified and pre-concentrated metabolite of MeSeA, B) 
aqueous mixture of GSH and MeSeA and C) synthesised S-(MeSe)Cys verified by NMR. The ion at 
m/z 240.8 is due to unresolved cysteine impurity also observed by NMR. (paper III) 
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LC-ESI-MS spectra of the reaction product between MeSeA and Cys, a synthesised S-(MeSe)Cys  
standard verified by NMR and the unknown metabolite from the incubation sample, were similar 
(figure 16). Hence, the identity of the metabolite was finally verified and it was clear that the 
metabolite is formed spontaneously upon reaction of MeSeA and Cys present in the intestinal 
epithelial cell homogenates.  
 
The other selenium containing compound observed in the soluble fraction of the epithelial cell 
homogenates, was tentatively identified by coelution when spiked with the reaction product of 
MeSeA and GSH. The reaction product of GSH and MeSeA was identified by LC-ESI-MSn as S-
(methylseleno)glutathione (S-(MeSe)SG).  
 
S-(MeSe)Cys has not been identified in mammal models before. It was first detected in yeast by 
the Uden group, who proposed the presence of a selenium-sulphur compound in selenized yeast 
after proteolytic digestion, derivatisation and analysis by GC-MS[69]. The identity of the compound 
was following verified by 77Se- and 1H-NMR after synthesis of a standard and it was proposed that 
the selenylsulfides are intermediates in the catalytic cycle of glutathione peroxidase[70]. It is 
proved now, however, that S-(MeSe)Cys is a product of spontaneous reduction of MeSeA by Cys as 
well. 
 
In conclusion, our studies showed that MeSeA like selenite was reduced by thiols Cys and GSH. 
Hence, MeSeA and selenite metabolism had more resemblance than the metabolism of MeSeA and 
SeMet, Se-MeSeCys or SeCys2. This finding questions the relevance of the use of MeSeA as a 
model compound for methylated Se-amino acids in cancer research. The in vitro intestinal 
metabolism studies show that SeMet and Se-MeSeCys either is taken up by epithelial cells in their 
Figure 17   Structures of the methylselenylsulfide S-(methylseleno)cysteine and the 
selenotrisulfide selenodicysteine 
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intact form or is metabolised to give either volatile selenium or selenium species associated to the 
insoluble fraction. Selenite and MeSeA however, are completely reduced when administered orally 
and will not be available for absorption in their intact forms.  
4.3 Hepatic metabolism 
The liver is the primary organ involved in the metabolism of xenobiotics and many compounds are 
taken up by hepatocytes and converted to pharmacologically inactive, active or toxic metabolites. 
Before entering the systemic circulation, absorbed species are directed via the portal vein to the 
liver. Hence, first pass hepatic metabolism plays a major role in bioavailability of ingested 
compounds. As hepatocytes contain the full complement of enzymes and cofactors that a 
compound is likely to encounter during first passage of the liver, they are physiologically relevant 
for in vitro metabolism studies[71].  
4.3.1 Methylseleninic acid (paper III) 
Cryopreserved rat hepatocytes were incubated with MeSeA and the insoluble fractions were 
analysed by a combination of LC-ICP-MS and LC-ESI-MSn experiments. The experiments and the 
results are submitted for publication in paper III. In cell medium, two metabolites (M1 and M2) 
were detected by LC-ICP-MS analysis. In the soluble fraction of methanolic cell lysates, two 
metabolites were detected (M1 and M3) (figure 18). The identities of metabolites M1 and M2 were 
tentatively established by chromatographic coelution with Se-MeSeCys and SeMet standards. It is 
important to notice that only about 15 % of the dosed selenium was recovered in the cell medium 
and even less was found in the soluble fraction of cell lysates (< 1 %). In fact, only about 25 % of 
the dosed selenium was accounted for by total selenium analysis of the medium, lysates and 
insoluble fraction. This indicates that about 75 % of the dosed selenium was lost, probably due to 
formation of volatile species. Infante et al[72] detected volatile selenium species 
dimethyldiselenide and dimethylselenide in the head space of lymphoma B-cells incubated with 
MeSeA, although no quantities were reported. Hence, formation of volatile selenium species by the 
hepatocytes is plausible. Preliminary experiments in which hepatocytes were incubated with MeSeA 
in the cell of a membrane inlet mass spectrometer (MIMS) with and electron impact (EI) ionisation 
source showed that large amounts of dimethyldiselenide was volatilised instantaneously from the 
incubation sample (results not published). 
 
The hepatocytes were incubated with a large amount of MeSeA in order to obtain metabolites in a 
concentration allowing identification by molecular mass spectrometry. The dose was far above any 
physiological relevance. However, the metabolic pattern was qualitatively similar to that obtained 
with relevant doses of MeSeA. Additionally, viability of hepatocytes was not significantly altered 
upon treatment with the high dose of MeSeA.  
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Identification of M1 – Se-MeSeCys 
LC-ESI-MS analysis of the purified and pre-concentrated metabolite M1 resulted in a spectrum with 
the characteristic selenium isotope pattern at m/z 184 corresponding to 80Se at the retention time 
of Se-MeSeCys. Isolation and fragmentation of the parent ion (m/z 184) led to formation of an 
intense ion at m/z 167, corresponding to loss of ammonia ([M-NH3]+). This ion was isolated and 
further fragmented in a MS3 experiment that resulted in fragment ions at m/z 149 [(M-NH3)-H2O]+, 
139 [(M-HN3)-CO]+, 123 [(M-NH3)-COO]+ and 95 [CH3Se]+ (figure 19). This fragmentation pattern 
was similar to the fragmentation pattern of a Se-MeSeCys standard. Similar MS2 and MS3 
experiments of parent ion m/z 182 for the 78Se compound also verified the extracted full scan 
selenium isotope pattern (table 2).   
 
S ta n d a rd S a m p le
M S 2
Iso la te d  m a ss  1 8 4 1 6 6 .9 1 6 6 .9
Iso la te d  m a ss  1 8 2 1 6 4 .9 1 6 4 .9
M S 3
Iso la te d  M a sse s  1 8 4 /1 6 7 1 4 9 .0 1 4 8 .9
1 3 8 .9 1 3 8 .9
1 2 2 .9 1 2 2 .8
9 5 .0 9 5 .1
Iso la te d  M a sse s  1 8 2 /1 6 5  - 1 4 6 .9
 - 1 3 7 .0
 - 1 2 1 .0
 - 9 3 .2
T a b le  2  L C -E S I-M S n d a ta  S e -M e S e C y s  
F ra g m e n t io n s  (m /z )
 
Figure 18   Hepatic metabolism of MeSeA. LC-ICP-MS chromatograms of the soluble fractions of cell 
medium (yellow) and cell lysate (black, offset by 40000 cps). Mobile phase: 20 mM ammoniumacetate 
in 2 % methanol. (paper III) 
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The major metabolite excreted from the hepatocytes upon incubation with MeSeA was Se-
MeSeCys. Infante et al also identified Se-MeSeCys as a metabolite of MeSeA in the lymphoma B-
cell line[72]. Hence, the capacity to produce Se-MeSeCys from MeSeA is not restricted to the very 
metabolically active cancer cells but is also present in normal healthy hepatocytes.  
 
Identification of M2 - SeMet 
Due to limited formation of metabolite M2 and limited amounts of incubation medium, the identity 
of this metabolite was established by two different molecular mass spectrometry approaches.   
 
Full scan LC-ESI-MS2 and LC-ESI-MS3 experiments were performed by use of an ion-trap 
instrument. Spectra in MS2 mode of a SeMet standard and the purified and concentrated metabolite 
M2 were similar (figure 20). Isolation and fragmentation of the parent ion (m/z 198.0) led to 
formation of an intense ion at m/z 180.9, corresponding to the loss of ammonia ([M-NH3]+). A 
Figure 19   LC-ESI-MSn spectra at retention time of Se-MeSeCys in purified and pre-
concentrated metabolite M1. Mobile phase: 0.1 % formic acid in 2 % methanol. (paper III) 
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minor fragment ion was observed at m/z 151.9 corresponding to parallel loss of formic acid ([M-
HCOOH]+). The major fragment ion (m/z 180.9) was isolated and further fragmented by LC-ESI-
MS3 analyses. In the MS3 mode, the extracted spectrum for M2 showed two fragment ions at m/z 
153.0 ([(M-NH3)-CO]+) and 109.1, corresponding to cleavage of the bond in α position to the Se 
atom ([CH3-Se-CH2]+). The fragment ion at m/z 135.0 ([(M-NH3)-HCOOH]+), observed with SeMet 
standard, did not appear.  The signal for the standard was approximately 104 times more intense 
than the signals for the metabolite. The low intensity for the sample was due to low concentration 
of the metabolite and probably also due to ion suppression in the biological sample. Although 
preparative chromatography was performed, it still contained salt and other interfering species.  In 
this LC-ESI-MSn experiment no peaks were observed in the total ion current (TIC) MS2 and MS3 
chromatograms at the expected retention time of SeMet. However, from the LC-ICP-MS analysis it 
was evident that the compound was present in the sample.  
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The LC-ESI-MSn experiments were not considered solid proof of metabolite identity and the data 
was supplemented with data from another LC-ESI-MS instrument with a triple quadrupole mass 
analyzer (QqQ). Based on LC-ESI-MS2 full scan spectra of a SeMet standard, three specific 
Figure 20   LC-ESI-MSn (ion trap) spectra of isolated and pre-concentrated metabolite M2. The 
mobile phase was 0.1 % formic acid in 2 % methanol. (paper III) 
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transitions from the parent ion to the fragment ions (obtained by collision induced dissociation) 
were selected for selected reaction monitoring (SRM) mode analysis. Figure 21 shows the SRM 
chromatograms of the selected transitions for the purified and pre-concentrated metabolite M2 and 
a SeMet standard of similar concentration. In all SRM experiments, transitions for parent ion 
corresponding to both 80Se and 78Se were monitored. The chromatographic peak at the retention 
time of SeMet was observed for all selected transitions. Although the same chromatographic setup 
(identical column and mobile phase) was used in the two LC-ESI-MS instruments, the retention 
time of SeMet was slightly displaced due to different void volumes of the two instruments. SRM is 
considered a rather selective detection method. However, the purified and pre-concentrated 
sample contained species that exhibited one or more SRM transitions selected for identification of 
SeMet. In this case specificity is ensured by chromatographic separation of the species and the 
relative intensity of the transitions is compared to that of a standard (figure 21).  
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The main fragment produced in the triple quadrupole instrument was m/z 109.0, whereas the main 
fragment produced in the ion trap (MS2 mode) was m/z 181.0. The m/z 109.0 fragment ion was 
Figure 21   LC-ESI-MS(SRM) (triple quadrupole) chromatograms of 750 ppb selenomethionine (blue scale) 
and of purified and pre-concentrated metabolite M2 (grey scale). The mobile phase was 0.1 % formic acid 
in 2 % methanol. (paper III) 
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only observed in the MS3 mode on the ion trap instrument. As these significant different 
observations were done for both the unknown species M2 and the SeMet standard, the evidence of 
the identity of the species is improved.  
 
The major drawback of molecular MS for identification of compounds is the need for reference 
spectra i.e. standard material must be available. Only limited structural information is available 
from MS for example typical losses identifying structural groups i.e loss of a methyl group (15 
mass units) and ammonia (17 mass units) may be identified but the position of the groups is not 
given. To circumvent the need for reference material NMR is the analysis of choice. However, 
samples for NMR analysis has to be very clean, which is often a major obstacle in bioanalysis. In 
this case SeMet and Se-MeSeCys standards were well characterized and commercial available and 
the identity of metabolites M1 and M2 were established.  
 
The lymphoma B-cells incubated with MeSeA by Infante et al[72] also produced SeMet. This 
observation was very surprising as it traditionally has been accepted that animals (including 
humans) were not capable of synthesizing SeMet but exclusively obtained it via food or nutritional 
supplements. Although MeSeA is not found in food and therefore not a part of the human selenium 
intake, the observation opens the question whether SeMet might be biosynthesized from other 
nutritionally available selenium compounds as well. 
 
A short time course study with low dose of MeSeA was performed. As all MeSeA was 
instantaneously metabolized it was not possible to determine any reaction kinetics from this study 
(figure 22). Formation of Se-MeSeCys was observed after 15 min and the amount increased over 
the one hour duration of the study. SeMet was not detected. Another selenium containing 
compound was detected. The peak decreased in size over time and it was not detected after 60 
min. A selenium containing compound was detected at limit of detection levels.  
 
The retention times of the compounds, that were only detected in the short time incubations, 
matched the retention time of synthesized S-(MeSe)Cys and S-(MeSe)SG, respectively. As the S-
Se metabolites were only observed in limited amounts it was not possible to prove their identity by 
LC-ESI-MS. Formation of these S-Se species would be expected as they are formed spontaneously 
upon reaction of MeSeA with Cys and GSH (paper II), that are present in large amounts in 
hepatocytes[51]. 
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The MeSeA metabolism was proposed by Sinha et al[2] to be a series of reductions by glutathione 
to S-(MeSe)SG and further to methylselenol (MeSeH). Methylselenol then undergoes oxidation or 
methylation to form the volatile species dimethyldiselenide (MeSe-SeMe) or dimethylselenide 
(MeSeMe) respectively. As mentioned earlier, the formation of these volatile metabolites of MeSeA 
in a lymphoma B-cell line has been verified by GC-MS by Infante et al[72]. Furthermore, the 
preliminary results from the experiments with the membrane inlet EI-MS revealed, that the large 
amount of volatilised dimethyldiselenide also was observed from an aqueous mixture of MeSeA and 
GSH. Hence, dimethyldiselenide was not a product of hepatocyte metabolism. It was rather a 
product of a series of spontaneous reactions initiated by the reduction of MeSeA by GSH (results 
not published). 
 
It is now clearly established that Se-MeSeCys and SeMet are derived from the metabolism of 
MeSeA in isolated rat hepatocytes. Hence, this observation should be included in metabolism 
models. As dimethylselenide and dimethyldiselenide are considered end products of selenium 
metabolism, there is reason to believe that MeSeA is metabolized through different pathways - one 
that leads to formation of volatile species, which may partly be due to spontaneous reduction by 
GSH and Cys, and pathways that lead to formation of Se-MeSeCys and SeMet and probably other 
not yet identified selenium species (figure 23). Selenoproteins and selenosugars are included in the 
metabolic pathways of MeSeA, as Suzuki et al. observed selenium of isotopically labelled MeSeA 
Figure 22   LC-ICP-MS chromatograms for time course study. The metabolites were eluted with a linear 
gradient of 0.1 % formic acid in 2 to 50 % methanol over 5 min followed by column equilibration in 0.1 % 
formic acid in 2 % methanol. Blue chromatogram represents a blank injection. (paper III) 
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origin in selenoproteins (extracellular glutathione peroxidase and selenoprotein P) and selenosugar 
in the rat[73,74]. 
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When MeSeA is used as a model compound for monomethylated selenium species in cancer 
research, caution must be taken not to misinterpret mechanistic findings caused by the initial 
reduction steps in MeSeA metabolism that are not relevant to Se-MeSeCys metabolism. In vitro, 
the initial reduction of MeSeA could result in depletion of intracellular GSH and thereby mimic a 
state of oxidative stress leading to activation of cancer chemopreventive mechanisms[75]. In vivo, 
however, MeSeA is reduced instantaneously by ubiquitously present thiol compounds i.e. luminal 
GSH when orally administered or in red blood cells after iv injection. Thus, intracellular GSH 
depletion in the target cancer cells will not occur. An important study regarding this different 
behavior in vivo and in vitro was published by Ip et al.[64]. They compared the cancer 
chemopreventive effect of Se-MeSeCys and MeSeA in vitro (mammary cancer cell lines) and in vivo 
(chemically induced mammary cancer in the rat) and found lack of congruency between the in vitro 
and in vivo results. Cell culture data showed that MeSeA was more potent in inhibiting growth and 
in inducing apoptosis, while this difference in efficacy disappeared in vivo. Also Shen et al.[68] 
related intracellular GSH to MeSeA induced apoptosis and demonstrated GSH depletion in 
hepatoma cells treated with MeSeA.  
Figure 23  Proposed metabolic scheme for MeSeA, a modified version of the model proposed by 
Sinha et al [2]. Structures of all the species in the figure is shown in paper IV. (paper III) 
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The finding that Se-MeSeCys is a metabolite of MeSeA in both healthy and cancer cells, indicate 
that MeSeA may not be a relevant model compound for Se-MeSeCys after all. Hence, there is no 
rationale in treatment with a precursor to methylselenol that in it self is metabolised into another 
precursor of methylselenol.  
 
It is important to notice that the results are obtained in models of epithelial cells from pigs and 
hepatocytes from rats. The in vitro – in vivo correlation as well as the animal – human correlation 
has not been investigated and is only speculative. 
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5 Conclusion 
SeMet and Se-MeSeCys were not decomposed when subjected to in vitro gastrointestinal digestion 
In two digestion models, selenite reacted differently; in one model selenite was extensively 
decomposed and in the other it was stable. Therefore SeMet, Se-MeSeCys and selenite are relevant 
compounds for intestinal metabolism studies. 
 
Selenite and MeSeA were completely reduced by Cys and GSH in the gastrointestinal tract and will 
not be bioavailable in their intact forms. The labile reduction products of selenite; GS-Se-SG and 
Cys-Se-SG were identified; however the degradation products were not detected as they were 
either volatilized or associated to insoluble cellular debris. Also the intermediate reduction products 
of MeSeA; S-(MeSe)Cys and S-(MeSe)SG were observed in intestinal epithelial cell homogenates. 
The identity of the former was established by molecular MS whereas the identity of the latter was 
tentatively established by chromatographic coelution with a standard. 
 
A new product, GS-Se-Se-SG in the series of reductions of selenite by glutathione was identified by 
molecular MS in an aqueous mixture of selenite and GSH. 
 
In hepatocytes, MeSeA was extensively metabolised and about 75 % of the dosed selenium was 
volatilized. Besides being spontaneously reduced by Cys and GSH, MeSeA was metabolised into the 
selenoamino acids Se-MeSeCys and SeMet. The selenoamino acids were excreted from the 
hepatocytes into the cell medium. Preliminary experiments indicated that MeSe-SeMe constitutes a 
significant part of the volatilized selenium and also that it was produced from the spontaneous 
reduction of MeSeA by GSH. Furthermore, the intermediate methylselenylsulfides S-(MeSe)Cys and 
S-(MeSe)SG of the spontaneous reduction of MeSeA by Cys and GSH were detected in the 
incubation medium of hepatocytes incubated with MeSeA.  
 
In conclusion, selenite and MeSeA are highly susceptible to spontaneous reduction by thiols. The 
series of reductions results in formation of a variety of selenium compounds and all of these are 
still not identified. The physiological relevance of the spontaneously formed selenium compounds 
has to be investigated. 
 
The findings in the intestinal and hepatic models combined indicate that MeSeA may not be a 
relevant model compound for Se-MeSeCys in cancer research, as the two compounds are 
metabolised by different pathways and MeSeA is metabolised into Se-MeSeCys. 
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It is important to notice that the results are obtained in models of epithelial cells from pigs and 
hepatocytes from rats. The in vitro – in vivo correlation as well as the animal – human correlation 
has not been investigated and is only speculative. 
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